Short answer
Pfizer Inc (PFE) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 28, 2026. Quarterly revenue was $15.0B (up 2.6% year over year) with net income of −$247M.
Q2 2026 key financials · XBRL
- Revenue
- $15.0B
- +2.6% YoY · +4.0% QoQ
- Net income
- −$247M
- −108.5% YoY · −109.2% QoQ
- EPS (diluted)
- −$0.04
- −107.8% YoY · −108.5% QoQ
Source: XBRL data from the Pfizer Inc (PFE) Q2 2026 10-Q on SEC EDGAR. USD.
Pfizer Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MD&A excerpt contains no quarterly revenue, profitability, segment, cash-flow, or outlook figures
Risk Factors
- No risk-factors section provided; excerpt begins with Item 2 and does not state whether risks materially changed
- Restructuring execution risk: additional Realigning Our Cost Base savings of $1 billion require approximately $2 billion in costs through 2029
- Manufacturing disruption risk: next optimization phase targets $1.5 billion savings with approximately $4.0 billion implementation costs through 2029
- Financial cost risk: manufacturing program costs comprise approximately 60% non-cash expenditures and 40% cash expenditures
- Forecast risk: restructuring savings, costs, timing, and potential additional charges remain subject to assumptions and may differ from expectations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pfizer Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.